FindTrial
Sign In

Wegovy 1 mg solution for injection in pre-filled pen

DRUG5 trials

Sponsors

Region Hovedstaden, Novo Nordisk A/S, Santiago Dexeus Font Fundacio Privada

Conditions

Cannabis dependence (Cannabis Use Disorder or CUD)InfertilityNon-alcoholic steatohepatitis (NASH)Obesity and Heart Failure with reduced Ejection FracitionObesity and overweightUnipolar depression Overweight and obesity

Phase 2

FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity
RecruitingCTIS2023-503753-35-01
Region HovedstadenObesity and Heart Failure with reduced Ejection Fracition
Start: 2024-03-20Target: 100Updated: 2025-08-22
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder
Not yet recruitingCTIS2025-524163-21-00
Region HovedstadenCannabis dependence (Cannabis Use Disorder or CUD)
Target: 100Updated: 2026-03-30

Phase 3

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Active, not recruitingCTIS2023-506962-30-00
Novo Nordisk A/SNon-alcoholic steatohepatitis (NASH)
Start: 2021-03-29Target: 219Updated: 2025-11-11
Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.
RecruitingCTIS2024-511734-13-04
Region HovedstadenObesity and overweight, Unipolar depression Overweight and obesity
Start: 2025-05-15Target: 120Updated: 2025-12-23

Phase 4

Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial
RecruitingCTIS2025-522525-34-00
Santiago Dexeus Font Fundacio PrivadaInfertility
Start: 2026-01-19Target: 62Updated: 2025-10-24